Shore Capital reaffirmed their hold rating on shares of AstraZeneca plc (LON:AZN) in a research note published on Friday.

Other analysts have also recently issued research reports about the stock. UBS AG set a GBX 5,150 ($66.86) price target on shares of AstraZeneca plc and gave the company a neutral rating in a research note on Thursday, April 27th. HSBC Holdings plc reissued a reduce rating and issued a GBX 4,200 ($54.52) price target on shares of AstraZeneca plc in a research note on Friday, May 5th. J P Morgan Chase & Co reissued a neutral rating on shares of AstraZeneca plc in a research note on Thursday, May 11th. Berenberg Bank increased their price target on shares of AstraZeneca plc from GBX 5,670 ($73.61) to GBX 5,850 ($75.94) and gave the company a buy rating in a research note on Wednesday, May 17th. Finally, Liberum Capital reissued a buy rating and issued a GBX 5,500 ($71.40) price target on shares of AstraZeneca plc in a research note on Tuesday, May 23rd. Three research analysts have rated the stock with a sell rating, nine have given a hold rating and nine have given a buy rating to the company’s stock. The stock currently has an average rating of Hold and an average price target of GBX 4,932.67 ($64.04).

Shares of AstraZeneca plc (LON:AZN) opened at 4447.00 on Friday. AstraZeneca plc has a 52 week low of GBX 3,996.00 and a 52 week high of GBX 5,520.00. The company’s market cap is GBX 56.30 billion. The firm has a 50-day moving average of GBX 4,818.59 and a 200 day moving average of GBX 4,863.31.

COPYRIGHT VIOLATION WARNING: This story was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this story on another website, it was copied illegally and reposted in violation of United States and international copyright and trademark law. The correct version of this story can be accessed at https://www.thecerbatgem.com/2017/08/21/astrazeneca-plc-azn-earns-hold-rating-from-shore-capital.html.

The company also recently disclosed a dividend, which will be paid on Monday, September 11th. Stockholders of record on Thursday, August 10th will be issued a GBX 68.90 ($0.89) dividend. The ex-dividend date of this dividend is Thursday, August 10th. This represents a dividend yield of 1.35%.

In other news, insider Nazneen Rahman acquired 39 shares of AstraZeneca plc stock in a transaction dated Thursday, July 27th. The shares were acquired at an average cost of GBX 4,370 ($56.73) per share, for a total transaction of £1,704.30 ($2,212.51).

AstraZeneca plc Company Profile

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Analyst Recommendations for AstraZeneca plc (LON:AZN)

Receive News & Stock Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related stocks with our FREE daily email newsletter.